Investment19 Mar 2026, 05:45 pm
Cipla Ltd. Announces Investment in Cipla (EU) Limited and Key Management Changes
AI Summary
Cipla Ltd. held a Board Meeting on 19th March 2026, where several key decisions were made. The company has approved an investment of up to USD 100 million in Cipla (EU) Limited, a wholly-owned subsidiary, for providing financial assistance to InvaGen Pharmaceuticals Inc. The board also approved a Scheme of Amalgamation of Inzpera Healthsciences Limited with the company. Mr. P R Ramesh has been designated as Vice-Chairman of the Company, and Mr. Robert Stewart has expressed his intention not to seek re-appointment as an Independent Director.
Key Highlights
- Cipla Ltd. to invest up to USD 100 million in Cipla (EU) Limited
- Investment aimed at providing financial assistance to InvaGen Pharmaceuticals Inc.
- Company approved a Scheme of Amalgamation of Inzpera Healthsciences Limited
- Mr. P R Ramesh designated as Vice-Chairman of the Company
- Mr. Robert Stewart to not seek re-appointment as Independent Director